The visualization of previously unappreciated PSMA-avid small lymph nodes in the pelvis, in both primary staging of prostate cancer and in the setting of biochemical recurrence post-definitive primary therapy, has raised interest in extended or targeted primary lymphadenectomy at time of primary prostatic surgery or as salvage lymphadenectomy. The gene discussed is FOLH1; the disease is prostate cancer.